Werewolf Therapeutics Receives FDA Fast Track Designation for WTX-124 for the Treatment of Advanced or Metastatic Solid Tumors

September 29, 2025

WATERTOWN, Mass., September 29, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”).

March 27, 2026

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

WATERTOWN, Mass., March 27, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

February 24, 2026

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

WATERTOWN, Mass., February 24, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

December 18, 2025

Werewolf Therapeutics Announces Pipeline and Business Updates

WATERTOWN, Mass., December 18, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)... Read More

Share this article: